Atea Pharmaceuticals (AVIR) Profit After Tax (2019 - 2026)

Atea Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$45.7 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 32.93% year-over-year to -$45.7 million; the TTM figure through Mar 2026 stood at -$169.7 million (down 21.55% YoY), while the FY2025 annual figure was -$158.4 million, up 5.91% from the prior year.
• Profit After Tax for Q1 2026 stood at -$45.7 million, down from -$44.9 million in the prior quarter.
• The five-year high for Profit After Tax was -$8.1 million in Q3 2022, with the low at -$63.2 million in Q1 2024.
• The 5-year median for Profit After Tax is -$35.5 million (2023), against an average of -$36.7 million.
• Peak annual rise in Profit After Tax reached 71.39% in 2022, while the deepest fall reached 2136.06% in 2022.
• Atea Pharmaceuticals' Profit After Tax stood at -$34.3 million in 2022, then decreased by 11.71% to -$38.3 million in 2023, then grew by 12.43% to -$33.5 million in 2024, then tumbled by 34.05% to -$44.9 million in 2025, then retreated by 1.74% to -$45.7 million in 2026.
• Business Quant data shows AVIR's Profit After Tax at -$45.7 million in Q1 2026, -$44.9 million in Q4 2025, and -$41.8 million in Q3 2025.